CAJ | 학술논문

中枢神经系统存在血脑屏障且缺乏淋巴组织和树突细胞,加之肿瘤周围建立的免疫抑制微环境,都使神经系统恶性胶质瘤的免疫治疗面临许多特殊的困难.以树突细胞为基础的免疫治疗是指树突细胞肿瘤疫苗的接种治疗,它可以部分或全部改善胶质瘤患者神经系统的免疫状况,因此可以成为有效的治疗方法.随着分子生物学和基因工程技术的发展,树突细胞肿瘤疫苗的制备、优化和应用技术得到了很大提高,为其未来临床应用奠定了良好的基础.
중추신경계통존재혈뇌병장차결핍림파조직화수돌세포,가지종류주위건립적면역억제미배경,도사신경계통악성효질류적면역치료면림허다특수적곤난.이수돌세포위기출적면역치료시지수돌세포종류역묘적접충치료,타가이부분혹전부개선효질류환자신경계통적면역상황,인차가이성위유효적치료방법.수착분자생물학화기인공정기술적발전,수돌세포종류역묘적제비、우화화응용기술득도료흔대제고,위기미래림상응용전정료량호적기출.
The immunotherapy for malignant glioma faces unique difficult, due to some anatomical and immunological charac teristics including the existence of blood brain barrier, the absence of lymphatic tissues and dendritic cells (DCs) in the central nervous system (CNS) parenchyma, and the presence of an immunosuppressive microenvironment. Therefore, immunotherapeutic approaches will not be beneficial unless the compromised immune status in malignant glioma patients is overcome. DC based immunotherapy, vaccinating cancer patients with DCs pulsed with various tumor antigens, is one of the most promising immunotherapeutic approaches for treatment of malignant glioma because it seems able to overcome, at least partially, the immunosuppressive state associated with primary malignancies. The preparation of DCs, choice of antigen, and route and schedule of administration are improving and optimizing with rapid development of molecular biology and gene engineering technology. DC vaccination in humans, after a number of pre-clinical models and clinical trials, would increase the clinica lbenefits for malignant glioma immunotherapy.